Stock Analysis
Black Diamond Therapeutics, Inc. (BDTX) Stock Analysis
Black Diamond Therapeutics, Inc. (BDTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Black Diamond Therapeutics, Inc. (BDTX) currently has an AIQ Score of 34/100, indicating a bearish setup. Momentum is the strongest factor at 42/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BDTX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $1.98 |
| AIQ Score | 34/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $116.9M |
| P/E Ratio | -2.76 |
| Forward P/E | — |
| EPS | -$0.17 |
| Revenue TTM | $0 |
| Dividend Yield | 0.00% |
| Beta | 3.29 |
| Volume | 590.1K |
| 52-week range | $1.60-$4.94 |
| RSI 14 | 34.46 |
| 50-Day SMA | $1.97 |
| 200-Day SMA | $2.36 |
| Analyst Price Target | $8.00 |
| Next Earnings | Nov 5, 2026 |
BDTX
OverviewBDTX Stock Analysis Summary
Black Diamond Therapeutics, Inc. (BDTX) currently has an AIQ Score of 34/100, indicating a bearish setup. Momentum is the strongest factor at 42/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, BDTX has AIQ Score of 34/100 with Momentum base of 42/100 and fading Quality at 27/100. Wait for component alignment before adding exposure.
Healthcare · 1.02% stock move · BDTX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BDTX Bullish or Bearish Right Now?
BDTX currently has a bearish overall setup. Momentum is the strongest factor at 42/100, while Quality is weakest at 27/100. The current evidence suggests a defensive setup.
- - Price is +0.57% above its 50-day SMA.
- - Analyst target implies +304.04% upside from the latest quote.
- - Momentum is weak at 42/100.
- - Risk Resilience is weak at 37/100.
- - Price is -16.11% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (31 vs 12).
Current Consensus
BDTX's Technical Analysis Consensus is currently Sell, with 12 buy, 2 neutral, and 31 sell votes. BDTX's 14-day RSI is 34.46, which places the stock in a weaker momentum range. BDTX's beta is 3.29, indicating greater market sensitivity than the broad market.
What Changed in BDTX?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the BDTX Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BDTX Decision Framework
Public evidence layers, setup checks, and risk context for Black Diamond Therapeutics, Inc..
Black Diamond Therapeutics, Inc. (BDTX) Stock Analysis
Black Diamond Therapeutics, Inc. has an AIQ Score of 34/100 in a Defensive regime. Momentum is strongest at 42/100. Beta is 3.29, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BDTX is in a Defensive AIQ regime with score 34/100. |
| Signal Conflict | The primary conflict is that momentum leads at 42/100 while quality lags at 27/100. |
| Factor Evidence | Momentum 42/100 · Quality 27/100 · Risk 37/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 42/100.
Momentum is 42/100 and RSI (14) is 34.5.
BDTX is in a Defensive regime at 34/100.
Risk factor is 37/100 with beta 3.29 and annual volatility 82.62%.
Current conflict: momentum leads at 42/100 while quality lags at 27/100.
BDTX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BDTX Fundamentals
BDTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BDTX Technical Analysis
BDTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BDTX Stock Catalysts
Track BDTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BDTX Dividend Analysis
BDTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BDTX Financial Data
BDTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BDTX Risk Analysis
BDTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BDTX Stock News
BDTX stock news, market tone, recent headlines, and catalyst context.
BDTX vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: BDTX · BEAM · CRSP · DNLI · DTIL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BDTX Current stock | 34/100 | — | 42/100 | 37/100 | -0.2 | 82.62% | Current |
| BEAM Beam Therapeutics | 32/100 | 34/100 | 23/100 | 36/100 | 0.56 | 75.17% | BDTX vs BEAM |
| CRSP CRISPR Therapeutics | 29/100 | 34/100 | 22/100 | 41/100 | 0.23 | 60.11% | BDTX vs CRSP |
| DNLI Denali Therapeutics | 37/100 | 34/100 | 31/100 | 70/100 | 0.86 | 56.56% | BDTX vs DNLI |
| DTIL Precision BioSciences | 49/100 | 60/100 | 31/100 | 51/100 | 0.8 | 72.10% | BDTX vs DTIL |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BDTX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BDTX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BDTX Stock FAQ
What is BDTX stock price today?
Black Diamond Therapeutics, Inc.'s current stock price is $1.98. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BDTX bullish or bearish right now?
BDTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BDTX's market cap?
BDTX's market cap is $116.9M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BDTX's current P/E ratio?
BDTX's current P/E ratio is -2.76 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BDTX's RSI?
BDTX's 14-day RSI is 34.46 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BDTX above its 50-day and 200-day moving averages?
BDTX is 0.57% from its 50-day SMA and -16.11% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BDTX's next earnings date?
BDTX's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BDTX pay a dividend?
BDTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.